DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Completed

Conditions: ALK-positive NSCLC

Interventions: Drug: crizotinib
Drug: alectinib
Drug: brigatinib
Drug: ceritinib
Drug: lorlatinib

First Posted Date: 2020-11-30

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 549

Registration Number: NCT04647110

Locations: 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Phase 2

Terminated

Conditions: Meningococcal Vaccine

Interventions: Biological: MenABCWY
Biological: Bivalent rLP2086 (60-µg Dose)
Biological: Bexsero
Biological: Bivalent rLP2086 (120-µg Dose)
Drug: Prophylactic Liquid Paracetamol (PLP)
Other: Placebo
Biological: Nimenrix
Drug: Therapeutic Liquid Paracetamol (TLP)
Drug: Scheduled Liquid Paracetamol (SLP)

First Posted Date: 2020-11-27

Last Posted Date: 2024-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 326

Registration Number: NCT04645966

Locations: 🇬🇷
P. & A. Kyriakou Children's Hospital, Athens, Greece
🇩🇪
Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche, Mannheim, Germany
🇬🇷
University General Hospital "ATTIKON", Athens, Greece

and more 18 locations

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 20vPnC

First Posted Date: 2020-11-24

Last Posted Date: 2024-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 839

Registration Number: NCT04642079

Locations: 🇺🇸
The Children's Clinic, Jonesboro, Arkansas, United States
🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸
Palmetto Pediatrics, PA, North Charleston, South Carolina, United States

and more 35 locations

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Phase 2

Terminated

Conditions: Achondroplasia

Interventions: Biological: Recifercept

First Posted Date: 2020-11-20

Last Posted Date: 2024-02-15

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT04638153

Locations: 🇮🇹
Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, Roma, Italy
🇺🇸
Nemours Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
🇵🇹
Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico, Coimbra, Portugal

and more 11 locations

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: talazoparib

First Posted Date: 2020-11-19

Last Posted Date: 2023-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04635631

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06651600

First Posted Date: 2020-11-18

Last Posted Date: 2021-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT04634565

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
North District of Peking University Third Hospital, Beijing, China

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07258669
Drug: Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2024-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04628793

Locations: 🇺🇸
QPS-MRA, LLC-Main Office, South Miami, Florida, United States

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Non-small-cell Lung Cancer
Urothelial Carcinoma
Colorectal Carcinoma
Ovarian Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma

Interventions: Biological: PF-07209960

First Posted Date: 2020-11-16

Last Posted Date: 2024-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04628780

Locations: 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
🇺🇸
The University of Texas MD Anderson Cancer Center- Investigational Pharmacy, Houston, Texas, United States

and more 10 locations

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07304814

First Posted Date: 2020-11-13

Last Posted Date: 2021-01-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04627532

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

Completed

Conditions: Gram Negative Infections

Interventions: Drug: Ceftazidime-avibactam

First Posted Date: 2020-11-13

Last Posted Date: 2024-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 189

Registration Number: NCT04628572

Locations: 🇮🇳
Fortis Hospital, Bhandup West, India
🇮🇳
Metro Hospital, Noida, India
🇮🇳
Grant Medical Foundation Ruby Hall Clinic, Pune, India

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy